Author

Sirus Rabbani

USE OF ANTI-ANDROGENIC 5ALPHA-REDUCTASE INHIBITORS AND RISK OF OESOPHAGEAL AND GASTRIC CANCER BY HISTOLOGICAL TYPE AND ANATOMICAL SUB-SITE
USE OF ANTI-ANDROGENIC 5ALPHA-REDUCTASE INHIBITORS AND RISK OF OESOPHAGEAL AND GASTRIC CANCER BY HISTOLOGICAL TYPE AND ANATOMICAL SUB-SITE

Sirus Rabbani

USE OF ANTI-ANDROGENIC 5Α-REDUCTASE INHIBITORS AND RISK OF OESOPHAGEAL AND GASTRIC CANCER BY HISTOLOGICAL TYPE AND ANATOMICAL SUB-SITE
USE OF ANTI-ANDROGENIC 5Α-REDUCTASE INHIBITORS AND RISK OF OESOPHAGEAL AND GASTRIC CANCER BY HISTOLOGICAL TYPE AND ANATOMICAL SUB-SITE

Sirus Rabbani  et al.

Item 1 - 2 / 2
1